ST snags lucrative licence

Specialised Therapeutics (ST) has struck a deal with Incyte Biosciences, the Swiss-based affiliate of Incyte to launch two new cancer therapies in three jurisdictions, including Australia.

Under the terms of the agreement, ST will be responsible for regulatory, distribution and local marketing related activities for tafasitamab (sold as Monjuvi in the US and Minjuvi in Europe) and Pemazyre in Australia, New Zealand and Singapore.

Local regulatory activities for both products, which address strong unmet needs in rare patient populations, are currently in progress said ST CEO Carlo Montagner.